Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics

Código QR

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics

Xinyu Fang, Yewei Wang, Yan Chen, Juanjuan Ren, Chen ZhangSchizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaObjective: Second-generation antipsychotics (SGAs) have a high risk of causing metabolic syn...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fang X, Wang Y, Chen Y, Ren J, Zhang C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	schizophrenia interleukin-6 metabolic syndrome second-generation antipsychotics Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c54246123f494991abd380a82d508820
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Tzu-Pei Yeh, et al.
Publicado: (2021)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Esquizofrenia y su asociación con enfermedades médicas crónicas
por: Orellana,Gricel, et al.
Publicado: (2017)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini F, et al.
Publicado: (2019)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Ping Yin, et al.
Publicado: (2021)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Stephan Hjorth, et al.
Publicado: (2021)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir S, et al.
Publicado: (2016)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Can melatonin prevent or improve metabolic side effects during antipsychotic treatments?
por: Porfirio MC, et al.
Publicado: (2017)

Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders
por: Emilia Vassilopoulou, et al.
Publicado: (2021)

Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
por: Takeshima M, et al.
Publicado: (2018)

Polimorfismos genéticos de interleuquina 6 (IL6), IL6R e IL18: asociación con componentes del síndrome metabólico en niños chilenos con obesidad
por: Suazo,José, et al.
Publicado: (2014)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward K, et al.
Publicado: (2019)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
por: Fan L, et al.
Publicado: (2021)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga S, et al.
Publicado: (2021)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020)

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications
por: Lei Chen, et al.
Publicado: (2021)

Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
por: Huang YC, et al.
Publicado: (2018)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
por: Xu H, et al.
Publicado: (2019)

A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
por: Liao X, et al.
Publicado: (2021)

One-Year Course of Olanzapine-Induced Diabetic Ketoacidosis: A Case Report
por: Mohammed Zain Ulabedin Adhoni, et al.
Publicado: (2021)

Drug Attitude, Insight, and Patient’s Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey
por: Nagai N, et al.
Publicado: (2020)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021)

Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
por: Bracha Erlanger Avigdor, et al.
Publicado: (2021)

A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study
por: Li Y, et al.
Publicado: (2021)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
por: Ohnishi T, et al.
Publicado: (2021)

Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia
por: Wang Y, et al.
Publicado: (2017)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
por: Shiraz Hussain, et al.
Publicado: (2021)

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
por: Findling RL, et al.
Publicado: (2018)

Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2020)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic M, et al.
Publicado: (2018)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko AS, et al.
Publicado: (2020)

Alteraciones metabólicas asociadas al uso de terapia antipsicótica
por: Rojas G,Paula, et al.
Publicado: (2009)